

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 2023 I on April 30, 2002

Paula F Durr Name of Person Mailing MAY 1 4 2002 14 DE

TECH CENTER 1600/2900

P&G Case AA399XM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of

George Endel Deckner, et al.

Serial No. 10/009,083

Filed March 20, 2002

Confirmation No. 5574

Group Art Unit 1615

Examiner

For Absorbent Article with Skin Care Composition

COPY OF PAPERS ORIGINALLY FILED

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents

Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. [] 37 C.F.R. §1.97 (b)(1) - U.S. Direct (within 3-months of filing a regular application or converted provisional)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(1), is being filed within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. [X] 37 C.F.R. §1.97 (b)(2) - Via PCT (within 3 mo. of Nat'l Stage Entry)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(2), is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application. Therefore, no fee is believed to be due.

3. [] 37 C.F.R. §1.97 (b)(3) - (>3 mo. after filing direct or nat'l stage entry, but before 1" O.A.)

This information disclosure statement is being submitted under 37 C.F.R. §1.97 (b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter is enclosed to facilitate charging of the fee, if necessary.

THE FOLLOWING IS ADDITIONAL INFORMATION PERTAINING TO (2) OR (3) MARKED WITH AN (X) ABOVE.

- (a) [X] The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that both a copy of the International Search Report and copies of the references cited therein are present in the national stage file. In accordance with MPEP §1893.03(g), it is respectfully requested that the Examiner note the consideration of these references in the first Office Action via the PTO-892 form.
- (b) [] The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that a copy of the International Search Report is present in the national stage file. Copies of the references cited in that report are enclosed.
- (c) [] The Notification of Acceptance of this Application Under 35 U.S.C. §371 does <u>not</u> indicate that a copy of the International Search Report and copies of the references cited are present in the national stage file. Copies of the International Search Report and references are attached.
- 4. [] 37 C.F.R. §1.97 (b)(4) (before the mailing of a first Office Action after the filing of a request for continued examination under §1.114)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(4), is being filed with the Request for Continued Examination (RCE) under 37 C.F.R. §1.114.

5. [] <u>Information to be Considered with CPA Filing</u>. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 CFR 1.53(d).

6.	[]	<u>37</u>	C.F.R.	§1.97(c)	with	fee	payment	- (use	after	1*	Office	Action	&	before
Final	Office A	Action	or Noti	ce of Allov	vance)									

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., Ex parte Quayle) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter is enclosed to facilitate the charging of the fee.

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

prior a	pplica y to sa	Copies of the cited references were previously cited by or submitted to the USPTO in ation Case No, U.S. Patent Application Serial No, filed Applicants claim aid application under 35 U.S.C. §120. Accordingly, copies of those documents are not the this Statement, pursuant to 37 C.F.R. §1.98(d).
		OR
[] ((2)	Copies of the cited documents are enclosed.
		OR
[] ((3)	Copies of all said documents, except document No.'s, were submitted and
consid	ered i	n parent application U.S. Patent Application Serial No, filed
Applic	ant(s)	claim priority to said application under 35 U.S.C. §120. Accordingly, copies of
docum	ent N	o.'s are not provided with this Statement, pursuant to 37 C.F.R.
§1.98(d). C	opies of document No.'s are enclosed. It is respectfully requested that
the cite	ed doc	cuments be carefully considered by the Examiner and made of record in this case.
[]	(4)	Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited at is not in the English language is provided.
	(5) ding a	Applicants also respectfully request the Examiner to consider and make of record the applications listed on the attached page.

Additional information is attached.

Respectfully submitted,

Kirsten K. Stone

Attorney or Agent for Applicant(s) Registration No. 42,129

(513) 634-5662

Date: April 30, 2002

Customer No. 27752

(IDS.doc) (Last Revised 12/7/01)

SHEET 1 of 1

COPY OF PAPERS ORIGINALLY FILED

PTO/SB08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

ratent and trademark office, of or salid OMB control number

Under the Paperwork Reduction Act of 1995, no persons as Substitute for form

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

equired to resp		s it contains a valid OMB control number					
	COMPLETE IF KNOWN						
	Application Number	10/009,083					
URE	Confirmation Number	5574					
ANT	Filing Date	March 20, 2002					
	First Named Inventor	George Endel Deckner, et al.					
	Group Art Unit	1615					
	Examiner Name						
	Attorney Docket Number	AA399XM					

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US-5.618.522	04-08-1997	Kaleta, et al.	
	1	US-5,643,588	07-01-1997	Roe, et al.	
	<u> </u>	US-			
	T -	US-		<u></u>	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.	FOREIGN PATENT DOCUMENT Country Code ³ Number ⁴ Kind Code ⁵ (if known)		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	⊤ ⁴
		DE 3309530 C1	10-25-1984	Leitner	<u> </u>	
		EP 0875233 A1	11-04-1998	Luu		ļ
	 	WO 97/38735 A1	10-27-1997	Schulz	Dra	
		WO 98/24390 A2	06-11-1998	Roe	UECEIV	
	 	WO 98/55158 A2	12-10-1998	Osborn	- OLIV	
	 	WO 99/12530 A1	03-18-1999	Van Rijswijck	May	
	 	WO 99/22684 A1	05-14-1999	Roe	MAY 1 4 20	h2
	 	WO 99/45973 A1	09-16-1999	Roe		72
	 				FCH CENTER	1/000

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				
EXAMINE	R	DATE CONSIDERED	<u> </u>			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.